Connection

Antonio Giordano to Drug Synergism

This is a "connection" page, showing publications Antonio Giordano has written about Drug Synergism.
Connection Strength

0.545
  1. Polo-like kinase 1 (Plk1) inhibition synergizes with taxanes in triple negative breast cancer. PLoS One. 2019; 14(11):e0224420.
    View in: PubMed
    Score: 0.157
  2. Targeted therapy based on p53 reactivation reduces both glioblastoma cell growth and resistance to temozolomide. Int J Oncol. 2019 Jun; 54(6):2189-2199.
    View in: PubMed
    Score: 0.151
  3. Abrogating G2/M checkpoint through WEE1 inhibition in combination with chemotherapy as a promising therapeutic approach for mesothelioma. Cancer Biol Ther. 2014 Apr; 15(4):380-8.
    View in: PubMed
    Score: 0.105
  4. Combined effects of PI3K and SRC kinase inhibitors with imatinib on intracellular calcium levels, autophagy, and apoptosis in CML-PBL cells. Cell Cycle. 2013 Sep 01; 12(17):2839-48.
    View in: PubMed
    Score: 0.102
  5. Nucleolin antagonist triggers autophagic cell death in human glioblastoma primary cells and decreased in vivo tumor growth in orthotopic brain tumor model. Oncotarget. 2015 Dec 08; 6(39):42091-104.
    View in: PubMed
    Score: 0.030
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.